Clinical Trial Search

Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants

Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects

Primary: Sustained Virologic Response (SVR) — 62 percentage of participants

Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants

Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale

Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036

Primary: Attributes of Treatment Experience — 14; 15; 7; 9 participants

Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L

Primary: Improvement in Scores on HCV Knowledge Questionnaire — 18.45; 19; 20.3; 21.75 Improvement in scores

Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027

Primary: Sustained Virologic Response After Treatment — 24 Participants

Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants

Primary: The Number of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (METAVIR Score) as Determined by Liver Biopsy After 12 Weeks of Treatment — 3; 6; 2…

Primary: Viral Response at Week 12 — 10 Participants

Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml

Primary: Adverse Event Profile of Repeated Dosing of CF102 — 6; 2; 2; 4 participants

Primary: HCV Antibody Test — 574 Participants

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr

Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants

Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants

Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317

Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants

Primary: Number of Participants With Sustained Virologic Response — 70 Participants

Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants

Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)

Primary: Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT) — 0; 5; 6 participants — p=0.0477

Primary: Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy — 59.5; 58.3 percentage of participants

Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale

Primary: Hepatitis C Virus (HCV) Cure (Sustained Virologic Response) — 158 Participants